[go: up one dir, main page]

CA3268292A1 - Long-acting formulations - Google Patents

Long-acting formulations

Info

Publication number
CA3268292A1
CA3268292A1 CA3268292A CA3268292A CA3268292A1 CA 3268292 A1 CA3268292 A1 CA 3268292A1 CA 3268292 A CA3268292 A CA 3268292A CA 3268292 A CA3268292 A CA 3268292A CA 3268292 A1 CA3268292 A1 CA 3268292A1
Authority
CA
Canada
Prior art keywords
long
acting formulations
formulations
acting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3268292A
Other languages
French (fr)
Inventor
Mukul Arun Ashtikar
Rudolf Josephus Dijmphna Leemans
Cleempoel An Van
Greet Lily Meurs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA3268292A1 publication Critical patent/CA3268292A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3268292A 2022-09-28 2023-09-27 Long-acting formulations Pending CA3268292A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22198411 2022-09-28
PCT/EP2023/076647 WO2024068699A1 (en) 2022-09-28 2023-09-27 Long-acting formulations

Publications (1)

Publication Number Publication Date
CA3268292A1 true CA3268292A1 (en) 2024-04-04

Family

ID=83506471

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3268292A Pending CA3268292A1 (en) 2022-09-28 2023-09-27 Long-acting formulations

Country Status (6)

Country Link
EP (1) EP4593834A1 (en)
JP (1) JP2025532272A (en)
CN (1) CN119968203A (en)
CA (1) CA3268292A1 (en)
TW (1) TW202423427A (en)
WO (1) WO2024068699A1 (en)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
BRPI0312927B8 (en) 2002-07-25 2021-05-25 Janssen Pharmaceutica Nv "compounds, quinoline derivatives, composition, their use as mycobacterial inhibitors, as well as process for preparing said derivatives".
WO2004105809A1 (en) 2003-05-22 2004-12-09 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
EE05394B1 (en) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Quinoline compounds for use in the treatment of latent tuberculosis
MX2007014874A (en) 2005-05-25 2008-02-15 Janssen Pharmaceutica Nv Process for preparing (alpha s, beta r)-6-bromo-alpha-[ 2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta- phenyl-3-quino lineethanol.
RS57111B1 (en) 2006-06-23 2018-06-29 Janssen Sciences Ireland Uc Aqueous suspensions of tmc278
PT2696848T (en) 2011-04-15 2020-09-03 Janssen Pharmaceutica Nv Freeze dried drug nanosuspensions
AU2018298855B2 (en) 2017-07-14 2024-07-18 Janssen Pharmaceutica Nv Long-acting formulations
AU2021303490A1 (en) 2020-07-09 2023-03-09 Janssen Pharmaceutica Nv Long-acting formulations
US20230355606A1 (en) 2020-07-09 2023-11-09 Janssen Pharmaceutica Nv Long-acting formulations

Also Published As

Publication number Publication date
JP2025532272A (en) 2025-09-29
TW202423427A (en) 2024-06-16
EP4593834A1 (en) 2025-08-06
CN119968203A (en) 2025-05-09
WO2024068699A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
GB202117828D0 (en) New formulations
GB202210794D0 (en) Lipid formulations
CA3268292A1 (en) Long-acting formulations
GB202204171D0 (en) Novel formulations
CA3265980A1 (en) Upadacitinib formulation
GB202018889D0 (en) Formulations
GB202009684D0 (en) Formulations
GB202009685D0 (en) Formulations
HK40094144A (en) Long-acting formulations
IL321617A (en) Bezuclastinib formulations
GB202315863D0 (en) Formulations
GB202307059D0 (en) Formulations
GB202216961D0 (en) 5-meo-mt formulations
PT3651736T (en) Long-acting formulations
GB202417829D0 (en) Formulations
GB202108259D0 (en) Novel formulations
CA3260005A1 (en) Paraben-free fexofenadine formulations
GB202115121D0 (en) Formulations
GB202115127D0 (en) Formulations
GB202004814D0 (en) Novel formulations
GB202004811D0 (en) Novel Formulations
GB202103780D0 (en) Formulations
GB202103762D0 (en) Formulations
GB202103785D0 (en) Formulations
GB202018250D0 (en) Formulations